Avellino Labs, a global biotechnology and precision medicine company, has named Chris Lehman as its new chief financial officer, it was reported yesterday.
Lehman has more than twenty-five years of financial and transactional experience in the biotechnology industry and will lead all financial aspects of Avellino Labs' expansion of disruptive genetic diagnostic and therapeutic technologies. He has led or supported 30 plus partnering, financing and M&A transactions, totalling USD600+ million primarily at top-tier biotechnology industry companies, including Coherus Biosciences, Quintiles, and Genencor International (acquired by DuPont de Nemours, Inc), and most recently served as CFO for Eureka Therapeutics. In addition to his experience with these companies, he founded his own successful business development strategy consultancy.
Gene Lee, chairman of Avellino Labs, said, 'Chris's financial leadership is key to our next phase of growth and to the success of our IPO expected later this year on the Korean stock exchange. His experience in the biotech space and in communicating with investors will prove invaluable as we shape our strategies and implement the operational expertise required to leap forward in our comprehensive diagnostic, therapeutic and big data programs.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business